^
Association details:
| Biomarker: | SEPTIN6-TRIM33 fusion |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas
Published date:
12/01/2021
Excerpt:
...significant difference in ORR was observed in patients with NPM1_NR4A3 and SEPT6_TRIM33 fusions...Histologically, 55 (69.6%) patients were diagnosed with DLBCL...Majorities of the patients received R-CHOP (34.2%) or R-COEP (27.8%) as their first-line therapy. Fifty-seven percentage of patients achieved CR (N=26) or PR (N=19) to treatments they received, while 8.9% of patient had a stable (SD, N=2) or progressive disease (PD, N=5), during a median follow-up of 7.08 months.
DOI:
https://doi.org/10.3389/fonc.2021.765544
